Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Change in Inventory (2016 - 2025)

Historic Change in Inventory for Fortress Biotech (FBIO) over the last 10 years, with Q3 2025 value amounting to -$1.0 million.

  • Fortress Biotech's Change in Inventory fell 14921.47% to -$1.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $30000.0, marking a year-over-year decrease of 9607.33%. This contributed to the annual value of $4.2 million for FY2024, which is 20688.08% up from last year.
  • As of Q3 2025, Fortress Biotech's Change in Inventory stood at -$1.0 million, which was down 14921.47% from $356000.0 recorded in Q2 2025.
  • Fortress Biotech's Change in Inventory's 5-year high stood at $12.0 million during Q2 2021, with a 5-year trough of -$2.7 million in Q3 2021.
  • Its 5-year average for Change in Inventory is $230157.9, with a median of -$823000.0 in 2022.
  • Data for Fortress Biotech's Change in Inventory shows a peak YoY increase of 263272.73% (in 2021) and a maximum YoY decrease of 162038.22% (in 2021) over the last 5 years.
  • Fortress Biotech's Change in Inventory (Quarter) stood at -$1.8 million in 2021, then skyrocketed by 38.87% to -$1.1 million in 2022, then grew by 23.62% to -$818000.0 in 2023, then surged by 423.11% to $2.6 million in 2024, then tumbled by 139.12% to -$1.0 million in 2025.
  • Its Change in Inventory was -$1.0 million in Q3 2025, compared to $356000.0 in Q2 2025 and -$1.9 million in Q1 2025.